<DOC>
	<DOCNO>NCT00001757</DOCNO>
	<brief_summary>Invasive fungal infection often life-threatening person immunocompromise . Persons prolong neutropenia secondary cytotoxic chemotherapy high risk infection . Patients undergo bone marrow transplantation , receive prolonged corticosteroid immunosuppressive therapy , person HIV infection AIDS also risk . With use currently approve antifungal therapy , many infection may still associate high mortality . Amphotericin B conventional form , current standard treatment life-threatening fungal infection . Because nephrotoxicity adverse effect , alternative conventional amphotericin B sought . Alternated agent include three lipid formulation amphotericin B , fluconazole , itraconazole . Although agent associated decrease adverse effect , efficacy life-threatening fungal infection show equivalent conventional amphotericin B. Voriconazole investigational antifungal drug currently bring phase III trial US . This azole show active many fungal pathogen vitro . In animal model early human trial new agent show effective aspergillosis . It show well-tolerated available intravenous oral formulation . This non-comparative , open label study evaluate efficacy , safety toleration voriconazole treatment invasive fungal infection . This agent use primary therapy fungal infection antifungal agent currently approve patient unable tolerate approve agent . Voriconazole also use secondary treatment patient fail therapy primary approve agent unable tolerate agent unacceptable toxicity .</brief_summary>
	<brief_title>An Open Label , Non-Comparative , Multicenter , Phase III Trial Efficacy , Safety Toleration Voriconazole Primary Secondary Treatment Invasive Fungal Infections</brief_title>
	<detailed_description>Invasive fungal infection often life-threatening person immunocompromise . Persons prolong neutropenia secondary cytotoxic chemotherapy high risk infection . Patients undergo bone marrow transplantation , receive prolonged corticosteroid immunosuppressive therapy , person HIV infection AIDS also risk . With use currently approve antifungal therapy , many infection may still associate high mortality . Amphotericin B conventional form , current standard treatment life-threatening fungal infection . Because nephrotoxicity adverse effect , alternative conventional amphotericin B sought . Alternate agent include three lipid formulation amphotericin B , fluconazole , itraconazole . Although agent associated decrease adverse effect , efficacy life-threatening fungal infection show equivalent conventional amphotericin B. Voriconazole investigational antifungal drug currently bring phase III trial US . This azole show active many fungal pathogen vitro . In animal model early human trial new agent show effective aspergillosis . It show well-tolerated available intravenous oral formulation . This non-comparative , open label study evaluate efficacy , safety , toleration voriconazole treatment invasive fungal infection . This agent use primary therapy fungal infection antifungal agent currently approve patient unable tolerate approve agent . Voriconazole also use secondary treatment patient fail therapy primary approve agent unable tolerate agent unacceptable toxicity .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Males ( nonpregnant ) female must least 18 Years age . Subjects must one follow systemic invasive fungal infection baseline : ( 1 ) systemic invasive infection due fungal pathogen currently license treatment ; ( 2 ) systemic invasive fungal infection , evidence failure and/or intolerance/toxicity treatment approve systemic antifungal agent . Definition failure treatment approve systemic antifungal agent : ) invasive aspergillosis invasive fungal infection : lack clinical response least 7 day systemic antifungal treatment adequate dos ; b ) Candida esophagitis : lack clinical response least 14 day fluconazole dose great equal 200 mg/day . Definition intolerance/toxicity treatment approve systemic antifungal agent : ) intolerance infusionrelated toxicity amphotericin B preparation despite appropriate supportive therapy ; b ) nephrotoxicity define serum creatinine increase great equal 1.5 mg/dl receive amphotericin B therapy c ) preexist renal impairment define serum creatinine increase great equal 2.0 mg/dl due reason amphotericin B . The systemic invasive fungal infection must present baseline document within four week precede study entry follow : ( 1 ) positive histopathology evidence tissue invasion fungal element , ( 2 ) positive serology diagnostic ( CSF cryptococcal antigen ; serum CSF Coccidioides antibody ; serum , CSF urine Histoplasma antigen ) , ( 3 ) positive mycologic culture normally sterile site , take current episode infection . Women child bear potential ( less 2 year postmenopausal ) must negative serum pregnancy test baseline , must agree use barrier method contraception study . Medical history must obtain baseline . Signed write informed consent must obtain baseline . Subjects must previously participate trial . Subjects must take unable discontinue follow drug least 24 hour prior randomization : terfenadine , cisapride , astemizole , sulphonylureas . Subjects must receive follow drug within 14 day prior randomization : rifampin , carbamazepine , barbiturates potent inducer hepatic enzyme result undetectable level voriconazole . Subjects must follow abnormality liver function test ( LFT 's ) : AST , ALT great 5 time upper limit normal ; alkaline phosphatase , total bilirubin great 5 time upper limit normal . Subjects must serum creatinine great 3.5 mg/dl endstage renal disease require chronic dialysis . Subjects must allergic bronchopulmonary aspergillosis , aspergilloma , zygomycoses , candiduria , and/or catheter devicerelated candidemia . Subjects must fungal infection consider invasive systemic include dermatophytosis oropharyngeal candidiasis . Subjects must receive likely receive investigational drug ( unlicensed new chemical entity ) , except one follow class medication : Cancer chemotherapeutic agent , antiretrovirals , therapy HIV/AIDSrelated opportunistic infection . Subjects must receive likely receive follow medication treatment study period : GCSF GMCSF ( treatment granulocytopenia ) , systemic antifungal medication white blood cell transfusion . Subjects must history hypersensitivity intolerance azole antifungal agent include miconazole , ketoconazole , fluconazole , itraconazole . Subjects must life expectancy le 72 hour . Subjects must condition , opinion investigator , could affect subject safety , preclude evaluation response , render unlikely contemplated course therapy complete .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1999</verification_date>
	<keyword>Azole</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Mycosis</keyword>
	<keyword>Invasive Fungal Infection</keyword>
	<keyword>Systemic Fungal Infection</keyword>
</DOC>